Paul Hartmann (PHH2.F) Stock Price

Paul Hartmann Price

XETRA·CLOSED
199.00EUR-1.00 (-0.50 %)
Market closed

Revenue has compounded at 3.6% per year over the past 19 years to 2.45 B EUR. Earnings per share have grown at 2.3% per year over the last 19 years. Paul Hartmann's net margin stands at 2.5%, down from 4.1% several years earlier. Paul Hartmann currently offers a dividend yield of about 4.02%. The payout ratio is around 46% of earnings. The dividend has grown at 4.8% per year over the past 19 years.

Paul Hartmann stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Paul Hartmann over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Paul Hartmann stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Paul Hartmann's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Paul Hartmann Stock Price History
DatePaul Hartmann Price
8/21/2026199.00 EUR
8/20/2026200.00 EUR
8/19/2026197.50 EUR
8/17/2026201.00 EUR
8/14/2026202.00 EUR
8/13/2026201.00 EUR
8/12/2026203.00 EUR
8/10/2026201.00 EUR
8/7/2026204.00 EUR
8/6/2026204.00 EUR
8/5/2026200.00 EUR
8/4/2026204.00 EUR
7/31/2026199.50 EUR
7/30/2026203.00 EUR
7/29/2026201.00 EUR
7/28/2026200.00 EUR
7/27/2026199.00 EUR
7/24/2026201.00 EUR
7/23/2026201.00 EUR
7/22/2026199.00 EUR
7/21/2026199.00 EUR
7/20/2026206.00 EUR
7/17/2026203.00 EUR
7/16/2026202.00 EUR
7/15/2026202.00 EUR
7/14/2026202.00 EUR
7/13/2026202.00 EUR
7/10/2026201.00 EUR
7/9/2026205.00 EUR
7/8/2026202.00 EUR
7/7/2026205.00 EUR
7/6/2026204.00 EUR
7/3/2026205.00 EUR
7/2/2026203.00 EUR
7/1/2026206.00 EUR
6/30/2026202.00 EUR
6/29/2026202.00 EUR
6/26/2026202.00 EUR
6/25/2026207.00 EUR
6/24/2026207.00 EUR
6/23/2026206.00 EUR
6/22/2026205.00 EUR
6/19/2026207.00 EUR
6/18/2026213.00 EUR
6/17/2026208.00 EUR
6/16/2026208.00 EUR
6/15/2026209.00 EUR
6/12/2026208.00 EUR
6/11/2026208.00 EUR
6/10/2026209.00 EUR
6/9/2026205.00 EUR
6/8/2026206.00 EUR
6/5/2026208.00 EUR
6/4/2026207.00 EUR
6/3/2026208.00 EUR
6/2/2026207.00 EUR
6/1/2026210.00 EUR
5/29/2026210.00 EUR
5/28/2026212.00 EUR
5/27/2026212.00 EUR
5/26/2026203.00 EUR
5/25/2026205.00 EUR
5/22/2026203.00 EUR
5/21/2026203.00 EUR
5/20/2026205.00 EUR
5/19/2026201.00 EUR
5/18/2026202.00 EUR
5/15/2026202.00 EUR
5/14/2026209.00 EUR
5/13/2026206.00 EUR
5/12/2026205.00 EUR
5/11/2026204.00 EUR
5/8/2026203.00 EUR
5/7/2026201.00 EUR
5/6/2026202.00 EUR
5/5/2026202.00 EUR
5/4/2026203.00 EUR
4/30/2026204.00 EUR
4/29/2026206.00 EUR
4/28/2026203.00 EUR
4/27/2026205.00 EUR
4/24/2026205.00 EUR
4/23/2026206.00 EUR
4/22/2026207.00 EUR
4/21/2026207.00 EUR
4/20/2026208.00 EUR
4/17/2026209.00 EUR
4/16/2026210.00 EUR
4/15/2026210.00 EUR
4/14/2026210.00 EUR
4/13/2026209.00 EUR
4/10/2026209.00 EUR
4/9/2026212.00 EUR
4/8/2026211.00 EUR
4/7/2026211.00 EUR
4/2/2026209.00 EUR
3/31/2026212.00 EUR
3/26/2026211.00 EUR
3/25/2026213.00 EUR
3/23/2026214.00 EUR
3/21/2026214.00 EUR
3/19/2026215.00 EUR
3/18/2026215.00 EUR
3/17/2026215.00 EUR
3/16/2026215.00 EUR
3/12/2026213.00 EUR
3/9/2026211.50 EUR
3/6/2026215.00 EUR
3/5/2026214.00 EUR
3/4/2026216.00 EUR
2/26/2026213.62 EUR
2/24/2026215.00 EUR
2/20/2026216.00 EUR
2/18/2026215.00 EUR
2/17/2026217.00 EUR
2/16/2026216.00 EUR
2/13/2026219.00 EUR
2/12/2026219.00 EUR
2/11/2026227.00 EUR
2/10/2026221.00 EUR
2/9/2026221.86 EUR
2/6/2026223.00 EUR
2/5/2026222.80 EUR
2/4/2026227.00 EUR
2/3/2026225.00 EUR
2/2/2026216.00 EUR
1/30/2026219.00 EUR
1/29/2026218.00 EUR
1/28/2026215.00 EUR
1/27/2026215.00 EUR
1/26/2026214.00 EUR
1/23/2026216.00 EUR
1/22/2026217.00 EUR
1/21/2026220.00 EUR
1/20/2026223.00 EUR
1/19/2026221.00 EUR
1/16/2026223.00 EUR
1/15/2026223.00 EUR
1/14/2026224.00 EUR
1/13/2026226.00 EUR
1/9/2026226.00 EUR
1/8/2026226.00 EUR
1/7/2026228.00 EUR
1/6/2026228.00 EUR
1/5/2026231.00 EUR
1/2/2026232.00 EUR
12/29/2025229.00 EUR
12/23/2025224.00 EUR
12/19/2025229.00 EUR
12/18/2025228.00 EUR
12/15/2025225.00 EUR
12/12/2025225.00 EUR
12/11/2025223.00 EUR
12/10/2025218.00 EUR
12/9/2025213.00 EUR
12/8/2025217.00 EUR
12/5/2025217.00 EUR
12/4/2025218.00 EUR
12/3/2025218.00 EUR
12/2/2025218.00 EUR
12/1/2025217.00 EUR
11/28/2025216.00 EUR
11/27/2025217.00 EUR
11/26/2025215.00 EUR
11/25/2025221.00 EUR
11/24/2025221.00 EUR
11/21/2025221.00 EUR
11/20/2025224.00 EUR
11/19/2025223.00 EUR
11/18/2025223.00 EUR
11/17/2025221.00 EUR
11/14/2025225.00 EUR
11/13/2025224.00 EUR
11/12/2025224.00 EUR
11/11/2025225.00 EUR
11/7/2025224.00 EUR
11/6/2025224.00 EUR
11/5/2025222.00 EUR
11/4/2025229.00 EUR
11/3/2025229.00 EUR
10/31/2025231.00 EUR
10/30/2025230.00 EUR
10/29/2025228.00 EUR
10/28/2025226.00 EUR
10/27/2025230.00 EUR
10/24/2025229.00 EUR
10/23/2025229.00 EUR
10/22/2025229.00 EUR
10/21/2025228.00 EUR
10/20/2025227.00 EUR
10/17/2025229.00 EUR
10/16/2025227.00 EUR
10/15/2025230.00 EUR
10/14/2025231.00 EUR
10/13/2025229.00 EUR
10/10/2025224.00 EUR
10/9/2025223.00 EUR
10/8/2025222.00 EUR
10/7/2025222.00 EUR
10/6/2025225.00 EUR
10/3/2025220.00 EUR
10/2/2025220.00 EUR
10/1/2025222.00 EUR
9/30/2025224.00 EUR
9/29/2025220.00 EUR
9/26/2025224.00 EUR
9/25/2025224.00 EUR
9/24/2025224.00 EUR
9/23/2025230.00 EUR
9/22/2025228.00 EUR
9/19/2025223.00 EUR
9/18/2025223.00 EUR
9/17/2025223.00 EUR
9/16/2025220.00 EUR
9/15/2025222.00 EUR
9/12/2025222.00 EUR
9/11/2025221.00 EUR
9/10/2025223.00 EUR
9/9/2025224.00 EUR
9/8/2025225.00 EUR
9/5/2025225.00 EUR
9/4/2025225.00 EUR
9/3/2025225.00 EUR
9/2/2025223.00 EUR
9/1/2025228.00 EUR
8/29/2025226.00 EUR
8/28/2025226.00 EUR
8/27/2025233.00 EUR
8/26/2025233.00 EUR
Access this data via the Eulerpool API
Get Free API Key

Paul Hartmann Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
2.12 B EUR
131.98 M EUR
79.02 M EUR
Jan 1, 2019
2.19 B EUR
113.22 M EUR
58.27 M EUR
Jan 1, 2020
2.43 B EUR
216.91 M EUR
106.48 M EUR
Jan 1, 2021
2.30 B EUR
142.03 M EUR
94.67 M EUR
Jan 1, 2022
2.31 B EUR
64.36 M EUR
36.15 M EUR
Jan 1, 2023
2.35 B EUR
63.37 M EUR
28.42 M EUR
Jan 1, 2024
2.41 B EUR
139.59 M EUR
108.45 M EUR
Jan 1, 2025
2.45 B EUR
97.51 M EUR
61.21 M EUR

Paul Hartmann Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 3:24 AM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
1.691.751.761.801.871.951.992.062.122.192.432.302.312.352.412.45
5.243.680.512.223.784.292.113.632.963.1611.30-5.430.431.822.291.74
56.0254.6653.9853.6454.9153.7857.4057.3957.5356.9156.6456.8456.6456.0159.8360.35
0.950.960.950.961.021.051.141.181.221.241.381.311.311.321.441.48
105.00107.0091.00110.00132.00122.00100.00142.00131.00113.00216.00142.0064.0063.00139.0097.00
6.226.125.186.127.086.275.046.906.185.178.886.172.772.685.773.96
65.0066.0050.0057.0073.0078.0084.0088.0079.0058.00106.0094.0036.0028.00108.0061.00
18.181.54-24.2414.0028.076.857.694.76-10.23-26.5882.76-11.32-61.70-22.22285.71-43.52
4.905.405.505.605.706.506.707.007.007.007.008.008.008.008.008.00
36.1110.201.851.821.7914.043.084.48–––14.29––––
3.603.603.603.553.553.553.553.551.783.553.553.553.553.553.553.55
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Paul Hartmann generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Paul Hartmann retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Paul Hartmann's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Paul Hartmann has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Paul Hartmann's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Paul Hartmann stock margins

The Paul Hartmann margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Paul Hartmann. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Paul Hartmann.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
57.56 %
6.23 %
3.73 %
Jan 1, 2019
56.93 %
5.18 %
2.66 %
Jan 1, 2020
56.66 %
8.92 %
4.38 %
Jan 1, 2021
56.85 %
6.17 %
4.11 %
Jan 1, 2022
56.67 %
2.78 %
1.56 %
Jan 1, 2023
56.01 %
2.69 %
1.21 %
Jan 1, 2024
59.81 %
5.80 %
4.50 %
Jan 1, 2025
60.38 %
3.98 %
2.50 %

Paul Hartmann Stock Revenue, EBIT, Earnings per Share

The Paul Hartmann earnings per share therefore indicates how much revenue Paul Hartmann has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
1,192.99 EUR
74.30 EUR
44.48 EUR
Jan 1, 2019
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2020
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2021
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2024
0.00 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
689.70 EUR
27.45 EUR
17.23 EUR

Paul Hartmann business model & stock analysis

Paul Hartmann AG is a company that operates in the healthcare industry and operates worldwide. The company was founded in 1818 by Paul Hartmann in Heidenheim an der Brenz as a hand weaving mill. The company quickly expanded and began producing medical dressings in the 1920s. Since then, the company has evolved into a leading provider of medical products and services. Paul Hartmann's business model is based on the idea of offering a comprehensive range of medical products and services. The products include medical consumables, wound and incontinence products, as well as disinfectants and cleaning agents. In addition, the company also offers medical services such as consulting, training, and support. Paul Hartmann AG operates in various segments. One of the most important segments is "wound care," in which the company offers a wide range of dressings and wound care products. The incontinence care segment includes products such as disposable diapers and incontinence briefs. In addition, the company also offers a range of personal care products that focus on the care of the elderly. The company has a strong focus on research and development. It invests in innovative technologies and is constantly seeking new products to improve the lives of patients and caregivers. Furthermore, the company is also committed to developing environmentally friendly products that focus on sustainability and resource conservation. A well-known product of Paul Hartmann AG is the "Dermaplast" brand, which offers medical dressings. The products are known for their good quality and craftsmanship and meet the highest medical standards. The "MoliCare" brand, a brand for incontinence care, is also well-known, offering high-quality products for intensive care for affected individuals. Overall, Paul Hartmann AG is headquartered in Heidenheim an der Brenz, but operates worldwide and employs over 11,600 people. The company is committed to offering a comprehensive range of medical products and services to improve the lives of patients and caregivers. The company has a long history and a strong focus on research and development, making it an important player in the healthcare industry.

Paul Hartmann SWOT Analysis

Strengths

Paul Hartmann AG operates with numerous strengths that contribute to its success and competitive advantage. These include:

  • Strong brand reputation and recognition in the market
  • Wide range of high-quality healthcare products and solutions
  • Established distribution channels and global presence
  • Innovative research and development capabilities
  • Strong financial performance and stability

Weaknesses

Despite its strengths, Paul Hartmann AG faces certain weaknesses that could potentially hinder its growth and competitiveness:

  • Dependency on specific markets or regions for revenue
  • Reliance on external suppliers for raw materials
  • Limited diversification in product portfolio
  • Higher production costs compared to some competitors
  • Potential challenges in managing and adapting to regulatory changes

Opportunities

Paul Hartmann AG has several opportunities that can be leveraged to further enhance its market position and growth:

  • Expanding into emerging markets with growing healthcare needs
  • Increasing focus on digital healthcare solutions and technology
  • Exploring strategic partnerships and collaborations for synergistic benefits
  • Enhancing product offerings with sustainable and eco-friendly options
  • Growing demand for healthcare products due to aging population and increasing healthcare spending

Threats

Paul Hartmann AG must be aware of the potential threats that could impact its operations and market position:

  • Intense competition from both established players and new entrants
  • Changing market dynamics and evolving customer preferences
  • Price pressures and cost management challenges
  • Economic uncertainties and fluctuations in exchange rates
  • Stringent regulations and compliance requirements

Paul Hartmann Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Paul Hartmann historical P/E ratio, EBIT multiple, and P/S ratio

Paul Hartmann annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Paul Hartmann shares outstanding

The number of shares of Paul Hartmann was 3.55 M in 2025. This indicates how many shares Paul Hartmann is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
1.78 M Stocks
Jan 1, 2019
1.78 M Stocks
Jan 1, 2020
1.78 M Stocks
Jan 1, 2021
1.78 M Stocks
Jan 1, 2022
1.78 M Stocks
Jan 1, 2023
1.78 M Stocks
Jan 1, 2024
1.78 M Stocks
Jan 1, 2025
3.55 M Stocks

Paul Hartmann Dividend History

23 years of dividend payments

YearAnnual DividendYoY ChangePayments
20258.00EUR 0.0%1×
May 2, 20258.00EUR 0.0%1/1
20248.00EUR 0.0%1×
20238.00EUR 0.0%1×
20228.00EUR 0.0%1×
20218.00EUR↑ 14.3%1×
20207.00EUR 0.0%1×
20197.00EUR 0.0%1×
20187.00EUR 0.0%1×
20177.00EUR↑ 4.5%1×
20166.70EUR↑ 3.1%1×

Paul Hartmann dividend history and estimates

In 2025, Paul Hartmann paid a dividend amounting to 8.00 EUR. Dividend means that Paul Hartmann distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2018
7.00 EUR
0.00 EUR
Jan 1, 2019
7.00 EUR
0.00 EUR
Jan 1, 2020
7.00 EUR
0.00 EUR
Jan 1, 2021
8.00 EUR
0.00 EUR
Jan 1, 2022
8.00 EUR
0.00 EUR
Jan 1, 2023
8.00 EUR
0.00 EUR
Jan 1, 2024
8.00 EUR
0.00 EUR
Jan 1, 2025
8.00 EUR
0.00 EUR

Paul Hartmann dividend payout ratio

In 2025, Paul Hartmann had a payout ratio of 46.42%. The payout ratio indicates the percentage of the company's profits that Paul Hartmann distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
15.74 %
Jan 1, 2019
31.09 %
Jan 1, 2020
31.08 %
Jan 1, 2021
36.20 %
Jan 1, 2022
37.90 %
Jan 1, 2023
40.17 %
Jan 1, 2024
41.50 %
Jan 1, 2025
46.42 %
Price targets and forecasts for Paul Hartmann are not yet available.

Paul Hartmann shareholder structure

% Name
0.07320%
Heidenheimer Volksbank eG
Heidenheimer Volksbank eG
0.02345%
MFS Investment Management
MFS Investment Management
0.00282%
Dr. Boss Finanz Management GmbH
Dr. Boss Finanz Management GmbH
0.00279%
Bessemer Trust Company, N.A. (US)
Bessemer Trust Company, N.A. (US)
0.00031%
Segall Bryant & Hamill, LLC
Segall Bryant & Hamill, LLC

Paul Hartmann Executives and Management Board

17 members · avg. age 63 · 47 % women

Management

BF

Ms. Britta Fuenfstueck

Chairman of the Management Board, Chief Executive Officer

–
ON

Mr. Oliver Neubrand

Chief Financial Officer, Member of the Management Board

–
MF

Ms. Monika Faber

Investor Relations

–

Board of Directors

FH

Mr. Fritz-Juergen Heckmann (69)

Chairman of the Supervisory Board

–
TB

Mr. Tobias Bucher

Deputy Chairman of the Supervisory Board, Employee Representative · since 2022

–
FG

Mr. Francois Georgelin

Member of the Management Board

–
SG

Mr. Stefan Grote (56)

Member of the Management Board

–
PB

Prof. Dr. Angelika Bullinger-Hoffmann

Member of the Supervisory Board

–
CG

Ms. Christine Geppert

Member of the Supervisory Board, Employee Representative

–

Frequently asked questions about Paul Hartmann

The business model of Paul Hartmann AG revolves around providing healthcare solutions and products. As a leading international supplier, Paul Hartmann AG specializes in medical and hygiene products, including wound care, incontinence management, surgical supplies, and hospital hygiene. The company focuses on improving patients' quality of life, supporting healthcare professionals, and delivering innovative solutions for various medical settings. With a strong commitment to sustainability and innovation, Paul Hartmann AG aims to contribute to the advancement of healthcare worldwide.

Paul Hartmann AG is primarily active in the healthcare and medical supplies industry.

The main competitors of Paul Hartmann AG in the market include companies such as Johnson & Johnson, B. Braun Melsungen AG, and Smith & Nephew PLC.

Paul Hartmann AG is a renowned company in the healthcare industry. Established in 1818, Paul Hartmann AG has a rich history spanning over two centuries. The company specializes in developing and manufacturing medical and hygiene products for professional and personal use. Over the years, Paul Hartmann AG has gained a strong reputation for its high-quality products and innovative solutions that enhance patient care. With a global presence, the company focuses on providing healthcare professionals and patients with reliable and effective products. Paul Hartmann AG continues to evolve and adapt to changing healthcare needs, staying true to its commitment to improving lives through its diverse product range.

Paul Hartmann AG, a leading global provider of medical and hygiene products, has achieved several significant milestones throughout its history. Established in 1818, the company has built a strong reputation for delivering innovative solutions in the healthcare industry. Over the years, Paul Hartmann AG has successfully expanded its global presence, becoming a trusted partner for medical professionals and institutions worldwide. The company's commitment to quality and continuous improvement has enabled it to develop advanced technologies and products that promote better patient care and infection prevention. With a rich heritage of over 200 years, Paul Hartmann AG continues to drive sustainable growth and make noteworthy contributions to the healthcare sector.

Paul Hartmann AG is primarily present across multiple countries and regions. These include Germany, France, the United Kingdom, Italy, Spain, Poland, Russia, and several other European countries. Additionally, the company has a strong presence in North America, South America, and Asia. With its global reach, Paul Hartmann AG serves as a leading provider of medical and hygiene products, catering to various healthcare facilities and consumers worldwide.

Paul Hartmann AG represents a strong commitment to delivering quality healthcare products and services. Their corporate philosophy revolves around innovative solutions, customer-centric approach, and sustainability. With a focus on patient care and safety, Paul Hartmann AG aims to provide reliable and effective healthcare solutions globally. The company believes in fostering long-term partnerships with healthcare professionals and organizations to improve the overall well-being of patients. By continuously evolving and adapting to the changing industry landscape, Paul Hartmann AG strives to create value for its customers, shareholders, and society as a whole.

The Paul Hartmann share (PHH2.F) is listed on 5 stock exchanges, including: XETRA (PHH2.DE), Frankfurt (PHH2.F), München (PHH2.MU), Stuttgart (PHH2.SG), Berlin (PHH2.BE).

The Paul Hartmann AG is a German company that specializes in the production of medical articles and products such as wound dressings and medical disposables. The company focuses on four different business areas: wound management, incontinence management, surgical cover and protection, and disinfection and hygiene. In the wound management sector, the company offers a wide range of state-of-the-art dressings and wound care products. These products range from simple band-aids to highly absorbent and rapidly diffusing wound dressings. The high-quality materials and unique technologies used in manufacturing ensure optimal wound care and accelerate the healing process. In the incontinence management sector, Hartmann provides disposable products for incontinence care. Here too, the company covers the entire spectrum from mild to severe cases. The products include specialized diapers, bed and underpads, as well as pads for men and women. Special emphasis is placed on skin care to avoid skin irritations and infections. In the surgical cover and protection category, Hartmann offers articles for the operating room, such as surgical gloves, masks, and clothing. The company places special emphasis on quality and safety. The products are tailored to the needs of all parties involved to ensure protection and comfort for everyone. Finally, the company also offers products for disinfection and hygiene. These include disinfectants, cleaning agents, and soaps for hospital use and general application. The products undergo strict regulations and are subject to approval by the relevant regulatory authorities. The business model of Paul Hartmann AG is based on providing high-quality and innovative medical products. The company places the highest value on quality and safety to provide optimal support to patients and medical professionals. Close cooperation with doctors and caregivers, as well as compliance with all legal regulations, ensures smooth operations in clinics, care facilities, and pharmacies. The company operates global distribution networks and works closely with all key market participants. Special focus is placed on research and development to continuously improve the products and meet the needs of customers. The company invests in modern technologies and efficient production processes to optimize costs while ensuring high-quality product standards. Overall, the business model of Paul Hartmann AG is a prime example of a successful company in the medical field. The commitment to quality, innovation, and customer service has made the company a significant player in the industry.

The revenue cannot currently be calculated for Paul Hartmann.

The profit cannot currently be calculated for Paul Hartmann.

The P/E ratio cannot be calculated for Paul Hartmann at the moment.

The P/S cannot be calculated for Paul Hartmann currently.

The Eulerpool Quality Score for Paul Hartmann is 3/10.

The ISIN of Paul Hartmann is DE0007474041. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Paul Hartmann is 747404. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Paul Hartmann is PHH2.F. The ticker symbol is used to trade Paul Hartmann shares on the stock exchange.

Over the past 12 months, Paul Hartmann paid a dividend of 8.00 EUR . This corresponds to a dividend yield of about 4.02 %. For the coming 12 months, Paul Hartmann is expected to pay a dividend of 8.00 EUR.

The current dividend yield of Paul Hartmann is 4.02 %.

Paul Hartmann pays a dividend, distributed in the months of , , , .

Paul Hartmann paid dividends every year for the past 23 years.

For the upcoming 12 months, dividends amounting to 8.00 EUR are expected. This corresponds to a dividend yield of 4.02 %.

Paul Hartmann is assigned to the 'Health' sector.

To receive the latest dividend of Paul Hartmann from amounting to 8 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Paul Hartmann distributed 8 EUR as dividends.

The dividends of Paul Hartmann are distributed in EUR.

All fundamentals and in-depth analysis of Paul Hartmann

Our stock analysis for Paul Hartmann stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Paul Hartmann. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Paul Hartmann Stock
Paul Hartmann Revenue→
Paul Hartmann Stock
Paul Hartmann Net Income→
Paul Hartmann Stock
Paul Hartmann P/E→
Paul Hartmann Stock
Paul Hartmann P/S→
Paul Hartmann Stock
Paul Hartmann EBIT→
Paul Hartmann Stock
Paul Hartmann Dividend→
Paul Hartmann Stock
Paul Hartmann Directors Dealings→
Paul Hartmann Stock
Paul Hartmann Stocks→
Paul Hartmann Stock
Paul Hartmann Market capitalization→
Paul Hartmann Stock
Paul Hartmann Debt→
Paul Hartmann Stock
Paul Hartmann Liabilities→
Paul Hartmann Stock
Paul Hartmann Equity→
Paul Hartmann Stock
Paul Hartmann AAQS→
Paul Hartmann Stock
Paul Hartmann Employees→
Paul Hartmann Stock
Paul Hartmann ROE→
Paul Hartmann Stock
Paul Hartmann ROA→
Paul Hartmann Stock
Paul Hartmann ROCE→
Paul Hartmann Stock
Paul Hartmann News→
Paul Hartmann Stock
Paul Hartmann Analyst Price Targets→

Health Stocks

PAVmedPatrysPaxman AB (publ)Patrangsit Healthcare Group PCLPCLPathfinder Cell TherapyPDS BiotechnologyPassage BioPeak ProcessingPasithea TherapeuticsPediatrix Medical GroupParnax LabAll Stocks A–Z →